Portfolio company Venatorx Pharmaceuticals out-licensed its Phase 3-ready oral antibiotic ceftibuten-ledaborbactam etzadroxil to Basilea Pharmaceutica for up to $325M in milestones.
Venatorx Pharmaceuticals, Inc
Venatorx Pharmaceuticals, Inc. is a private pharmaceutical company focused on improving health outcomes for patients with multi-drug-resistant bacterial infections and hard-to-treat viral infections.